Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
01 Abril 2024 - 6:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that members of management will participate in a
fireside chat at the 23rd Annual Needham Healthcare Conference on
Monday, April 8 at 10:15 a.m. ET.
A live webcast of the fireside chat, as well as an
archived recording, will be available on Avadel’s Investor
Relations website, investors.avadel.com, for 90 days following the
conference.
About Avadel Pharmaceuticals
plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a
biopharmaceutical company focused on transforming medicines to
transform lives. Our approach includes applying innovative
solutions to the development of medications that address the
challenges patients face with current treatment options. Avadel’s
commercial product, LUMRYZ™, was approved by the U.S. Food
& Drug Administration (FDA) as the first and only
once-at-bedtime oxybate for the treatment of cataplexy or excessive
daytime sleepiness (EDS) in adults with narcolepsy. For more
information, please visit www.avadel.com.
Investor Contact:Courtney
MogerleyStern Investor Relations, Inc.Courtney.Mogerley@sternir.com
(212) 698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com(609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Gráfica de Acción Histórica
De May 2023 a May 2024